BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22252562)

  • 1. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
    J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
    Hearn JW; Videtic GM; Djemil T; Stephans KL
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):402-6. PubMed ID: 25017480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.
    Robinson CG; DeWees TA; El Naqa IM; Creach KM; Olsen JR; Crabtree TD; Meyers BF; Puri V; Bell JM; Parikh PJ; Bradley JD
    J Thorac Oncol; 2013 Feb; 8(2):192-201. PubMed ID: 23287852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat stereotactic body radiation therapy for patients with pulmonary malignancies who had previously received SBRT to the same or an adjacent tumor site.
    Valakh V; Miyamoto C; Micaily B; Chan P; Neicu T; Li S
    J Cancer Res Ther; 2013; 9(4):680-5. PubMed ID: 24518717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
    Parks J; Kloecker G; Woo S; Dunlap NE
    Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
    Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence.
    Shintani T; Matsuo Y; Iizuka Y; Mitsuyoshi T; Mizowaki T
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1228-1236. PubMed ID: 29722662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Takayama K; Norihisa Y; Mizowaki T; Narabayashi M; Sakanaka K; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1104-11. PubMed ID: 20472343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.
    Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Bando T; Date H
    Ann Surg Oncol; 2014 Aug; 21(8):2546-54. PubMed ID: 24633668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.
    Kastelijn EA; El Sharouni SY; Hofman FN; Van Putte BP; Monninkhof EM; Van Vulpen M; Schramel FM
    Anticancer Res; 2015 Oct; 35(10):5607-14. PubMed ID: 26408733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.